Guidelines for the management of diffuse large B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q54708579

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Guidelines for the management of diffuse large B-cell lymphoma.

@en

Guidelines for the management of diffuse large B-cell lymphoma.

@nl

type

Item

label

Guidelines for the management of diffuse large B-cell lymphoma.

@en

Guidelines for the management of diffuse large B-cell lymphoma.

@nl

prefLabel

Guidelines for the management of diffuse large B-cell lymphoma.

@en

Guidelines for the management of diffuse large B-cell lymphoma.

@nl

P1476

Guidelines for the management of diffuse large B-cell lymphoma.

@en

P2093

Andrew McMillan

http://www.w3.org/2001/XMLSchema#string

Andy Davies

http://www.w3.org/2001/XMLSchema#string

Karl Peggs

http://www.w3.org/2001/XMLSchema#string

Kate Cwynarski

http://www.w3.org/2001/XMLSchema#string

Pam Mckay

http://www.w3.org/2001/XMLSchema#string

Simon Stern

http://www.w3.org/2001/XMLSchema#string

Sridhar Chaganti

http://www.w3.org/2001/XMLSchema#string

Tim Illidge

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Stromal gene signatures in large-B-cell lymphomas

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

P304

43-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14136

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P50

Kim Linton

Sally Barrington

British Committee for Standards in Haematology

P577

2016-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27196701

http://www.w3.org/2001/XMLSchema#string